비PVC IV백 시장 : 예측(2023-2028년)

The global non-PVC IV bags market was valued at US$1.149 billion in 2021.

The non-PVC IV bags market is anticipated to grow at a steady pace throughout the forecast period. Intravenous bags produced from substances other than polyvinyl chloride (PVC) are known as non-PVC IV bags. Non-PVC IV bags are often created from substances that are less dangerous to human health, such as polyolefins, polyurethane, and polyethersulfone. The rising number of cancer cases and other chronic diseases such as kidney failure are major factors in the non-PVC IV bags market as the therapy in the treatments in these conditions requires IV bags.

Rising Cancer Cases

The non-PVC IV bags market is impacted by the growth in cancer cases in the population as well as the surge in demand for oncology processes, particularly for chemotherapy and targeted drug delivery. For instance, one in six deaths, or around 10 million deaths, was due to cancer in 2020, making it the top cause of death globally as per the WHO. In low and lower-middle-income nations, cancer-causing infections including the human papillomavirus (HPV) and hepatitis are estimated to be the cause of 30% of cancer cases. Non-PVC IV bags are less harmful concerning the contamination thus it is safe to use non-PVC IV bags.

Growing Burden of Chronic Diseases

The growing prevalence of chronic diseases such as kidney failure which require dialysis is expected to drive the non-PVC IV bags market in the coming years. For instance, in the United States, 37 million adults which is more than 1 in 7 have chronic kidney disease (CKD). The risk of CKD is even higher for Americans who have either diabetes or high blood pressure, the two main causes of kidney disease. Moreover, chronic obstructive pulmonary disease (COPD), the third highest cause of mortality globally, kills approximately 90% of those under the age of 70 in low- and middle-income (LMIC) countries, according to World Health Organisation (WHO) updates 2022. Due to the predicted rise in demand for non-PVC IV bags used to provide intravenous fluids to patients undergoing heart surgery and those being treated for acute exacerbations, the market is expected to develop.

Government Efforts to Increase the Use of Non-PC IV Bags

The non-PVC IV bags market is also being boosted by rigorous regulations governing the use and disposal of PVC and improved healthcare infrastructure in developing nations. It has been determined by several government agencies and expert panels in Europe, the US, Canada, and Japan that several medical treatments that expose patients to DEHP may be harmful to their health. For instance, to protect premature infants and newborns, the German Federal Institute for Drugs and Medical Equipment (BfArM) advises against using medical equipment made of DEHP-softened PVC. Additionally, BfArM asks producers of medical devices to disclose the presence of DEHP in their goods and to invest more time and energy in creating safer substitutes.

Opportunities in the Market

These growth factors mentioned above are predicted to provide an immense opportunity in the non-PVC IV bags market expansion. Apart from these factors, the growing awareness among patients about the harmful effects of plastic bags further indicates the growth in the non-PVC IV bags market. Packaging frequently uses PVC materials. However, because they cannot decompose, their disposal has a detrimental effect on the environment. Due to growing environmental concerns, eco-friendly PVC replacements are being developed, which is fueling the expansion of the non-PVC IV bag market globally. For instance, to advance sustainability in healthcare across Europe, VinylPlus Med officially inaugurated its pilot medical PVC recycling program in Belgium in October 2021. This program will recycle discarded single-use PVC medical devices, such as oxygen and anaesthetic masks, tubing, IVs, and dialysis bags.

Restraints in the Market

Few factors are expected to limit the non-PVC IV bags market growth. The leached DEHP molecules from the PVC tube during intravenous infusion of aqueous drug solutions produce many harmful health effects, including but not limited to a disruption in human metabolism. Additionally, non-PVC infusion sets do not carry the DEHP molecules, which causes unfavourable health effects.

North America is Expected to Grow Significantly

The North American region is supposed to hold a significant share of the non-PVC IV bags market during the forecast period. Various factors attributed to such a share are rising cancer cases, awareness about the hazardous effects of PVC IV bags, and stringent government regulations. For instance, around 1.9 million new cancer cases are anticipated to be diagnosed in 2023 in the US as per the American Cancer Society. Using alternatives to DEHP-containing devices for specific, susceptible individuals is advised by the US Food and Drug Administration, according to an FDA Safety Assessment and a Public Health Notification. Moreover, the presence of market leaders such as Baxter and ICU Medical is further predicted to propel the non-PVC IV bags market in the region.

Major Market Players

• Baxter offers a range of acute, nutritional, renal, and surgical care products to advance healthcare around the globe. It offers more than 200 active codes for fluid therapy such as 0.9% sodium chloride injection in both Viflex and Viaflo containers (non-PVC), dextrose for injection, lactated ringers & ringers, OSMITROL, Plasmalyte, sterile water, and potassium chloride in dextrose & sodium injections. It also provides an IV solution for the drug reconstitution system.
• ICU Medical, a US-based medical company focussed on IV therapy. Its IV solutions are produced in two US plants with reliable delivery in just one to two days in the US. It offers Supercath 5 IV Catheter, Y-Connector, Vial Adapter with Clave™, Double Female Connector, Supercath 5 IV Catheter, and others.

Key Market Developments

• In June 2022, dual chamber IV bags made of polypropylene (DEHP free) with a peelable aluminium foil were introduced by Gufic Biosciences in India. These bags allow the storage of unstable medications that need to be reconstituted right before administration at the point. This is a brand-new medicine delivery technology that India intends to produce domestically.
• In September 2021, B.Braun launched a non-PVC IV set, CARESAFE IV Administration Sets with optional AirStop to reduce patient exposures to toxic substances which was the first in the US market. It helps keep the line from drying out because it is made to only let fluid pass.
• In November 2020, Fagron Sterile Services launched a new product platform named Intravenous (IV) Bags for the continued expansion of its product portfolio in 2021. It is committed to supply agreements offered with a 98% on-time delivery rate and products individually wrapped for extended beyond-use dating and product protection.

Segmentation:

By Product

• Single Chamber
• Multi-Chamber

By Material

• Ethylene Vinyle Acetate
• Polypropylene
• Copolyester ether
• Others

By Content

• Frozen Mixture
• Liquid Mixture

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

• 2.1. Research Data
• 2.2. Assumptions

3. EXECUTIVE SUMMARY

• 3.1. Research Highlights

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Force Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. NON-PVC IV BAGS MARKET, BY PRODUCT

• 5.1. Introduction
• 5.2. Single Chamber
• 5.3. Multi Chamber

6. NON-PVC IV BAGS MARKET, BY MATERIAL

• 6.1. Introduction
• 6.2. Ethylene Vinyle Acetate
• 6.3. Polypropylene
• 6.4. Copolyester ether
• 6.5. Others

7. NON-PVC IV BAGS MARKET, BY CONTENT

• 7.1. Introduction
• 7.2. Frozen Mixture
• 7.3. Liquid Mixture

8. NON-PVC IV BAGS MARKET, BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. United States
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. United Kingdom
  • 8.4.2. Germany
  • 8.4.3. France
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. The Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Israel
  • 8.5.4. Others
• 8.6. Asia Pacific
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Emerging Players and Market Lucrativeness
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

• 10.1. Baxter
• 10.2. B. Braun Melsungen AG
• 10.3. ICU Medical
• 10.4. Fresenius Kabi AG
• 10.5. JW Life Science
• 10.6. RENOLIT
• 10.7. PolyCine GmbH
• 10.8. Sealed Air
• 10.9. ANGIPLAST PVT. LTD